A research study focused on magic mushrooms in Canada revealed that nearly 80% of the participants are of the opinion that psilocybin, the active ingredient in magic mushrooms, should be medically available for distressed patients. Moreover, about two-thirds of the Canadian participants from the same study concurred that psilocybin should be legally accessible for those who need it.
Besides advocating for wider availability of the substance, an impressive 84.8 percent of participants felt that the public health system should bear the costs of such therapies. A substantial number of Canadians view psilocybin as a credible option, particularly for treating end-of-life distress.
[toc]
Key Takeaways:
- Inhabitants of Québec, Ontario, Alberta, and British Columbia consider psilocybin as a legitimate medical option for dealing with end-of-life existential distress.
- Magic mushrooms are perceived to be safe for treating existential distress.
- Participants in two double-blind trials experienced immediate and long-lasting benefits, with effects persisting for six months or more.
A Close Look at Existential Distress
Existential distress, similar to existential suffering, spiritual distress, and demoralization, manifests when individuals are faced with their mortality. This can lead to feelings of helplessness, isolation, anxiety, and a sense of lost meaning and purpose. Such distress is particularly prevalent among patients with life-threatening illnesses, potentially leading to a wish to hasten death or consider suicide.
Generally, individuals grappling with terminal illnesses or significant life changes are the most prone to this type of distress. It significantly impacts their mental health and overall quality of life.
Existential therapy aims to tackle issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. Despite requiring multiple sessions, it might not be effective for everyone.
The uncertain outcomes of such therapy are a key reason why many individuals seek alternative treatments.
Health Canada’s Stance on Psilocybin as a Therapeutic Option
In the last two decades, preliminary clinical trials have highlighted the potential advantages of psychedelic substances for treating complex mental disorders. Specifically, Psilocybin has demonstrated a quick and lasting relief from existential distress in patients approaching their life’s end.
Recognizing the potential efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments are ineffective, Health Canada revised the Special Access Program in 2022. This revision permits healthcare professionals to request controlled substances for their patients.
Canadian Advocacy for Psilocybin Access
A study published in the Palliative Care Journal evaluates societal views on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Methodology | Input from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of these participants had previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% view psilocybin-assisted therapy as a legitimate medical option for addressing end-of-life existential distress. 63.3% think that psilocybin should be integrated into medical treatment. 84.8% endorse the delivery of this therapy by the public health system. 44.2% believe that healthcare professionals should administer the substance without Health Canada’s supervision. |
The study’s findings align with surveys conducted in Canada, England, and Australia. The researchers stressed that their study is distinct as it focuses on the use of psychoactive substances for treating existential distress in end-of-life situations.
Why Canadians Support the Use of Psilocybin
An increasing number of Canadians are advocating for the use of psilocybin as a treatment method, primarily due to evidence presented by reputable research institutions. Another factor is the perceived safety of psilocybin mushrooms in mitigating existential distress. Participants across various studies have not reported severe negative health effects, such as multi-organ failure.
| Study | Approach | Results |
| Johns Hopkins Study | 51 patients received a high dose of psilocybin and a low dose as an active placebo control | Immediate and long-lasting The therapeutic benefits of this therapy, which can last up to six months or even longer, are largely ascribed to mystical experiences that induce a sense of unity and deep emotional enlightenment. |
| Trial at New York University | 29 patients were randomly chosen to either receive psilocybin or the active placebo, niacin. | The results of this study echoed those of the Johns Hopkins study. Patients who received psilocybin reported psychological relief and a more positive outlook on life and death. |
| BMC Palliative Care | Nineteen participants (which included 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and a psychologist) were interviewed. The purpose of the study was to gain insight into how professionals in palliative care perceive existential distress and their views on psychedelic therapy as a treatment option. | Psychedelic-assisted therapy (PAT) is seen by palliative care professionals as a potential method to alleviate existential distress, according to the results. |
Patient Experiences
Apart from scientific studies, patient accounts also provide substantial evidence supporting the efficacy of psilocybin in enhancing mental wellness and improving the quality of life.
The Journey of Yokoi
Mio Yokoi, a patient living with terminal stage 4 pancreatic cancer, shares her transformative experience during her assisted therapy. She visualized herself on a raft, surrounded by nature and friendly, imaginary creatures. This vision cultivated a profound understanding of the interconnectedness and supportive nature of the universe, which brought her immense peace and validation.
Despite availing traditional mental health services, Yokoi had continued to suffer from severe anxiety and distress post-diagnosis. Psilocybin therapy enabled her to reconnect with her body and provided a tangible feeling of love and support, significantly improving her emotional and mental well-being.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. She was employed as an administrative supervisor in healthcare at the time of the study and identified as an atheist. Her screening included a diagnosis of Generalized Anxiety Disorder.
Chrissy experienced significant reductions in her anxiety, depression, fear of death, hopelessness, and demoralization levels. When asked if her therapy session had brought about any changes in her religious or spiritual beliefs, she shared that the experiences had brought a sense of purpose and authenticity to her beliefs.
Brenda’s Journey
Brenda underwent therapy sessions during which she experienced the sensation of dying twice. These experiences led to a change in her perspective on death, which she began to see as a natural part of the cycle of life. She credited the study with catalyzing her healing process from childhood trauma, a shift that was reflected in her data. Reportedly, her anxiety and fear of death decreased, while her sense of spirituality increased.
Availability of Magic Mushroom Products in Canada
At present, the supply of psilocybin capsules and other products designed to alleviate existential distress or mental health problems may be limited. However, reliable online dispensaries remain a viable source for obtaining these products as needed.
| Attributes | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and nearby South American nations. | Discovered in Cambodia, near the Angkor Wat Temple. | Related to the Penis Envy mushrooms that became popular in the 1970s. |
| Potency | Moderately potent; suitable for beginners. | Similarly moderate in potency; ideal for first-time users. | Extremely potent; recommended for users with an intermediate to advanced level of experience. |
| Effects | Produces a mental buzz, slight disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and improved focus. | Causes an energizing, long-lasting high, minor visual changes, increased creativity, euphoria, a gentle physical high, fractal imagery, and feelings of joy. | Leads to profound shamanic experiences, vision quests, intense mystical experiences, increased creativity, focus, social awareness, and mood enhancement. |
Mitigating End-of-life Distress with Psilocybin Products
Existential or end-of-life distress can exert a considerable burden on patients nearing the end of their lives. Conventional treatments for this distress may not always be sufficient, leading to increased support in Canada for easier access to magic mushrooms within the public healthcare system. The rising public interest could
We encourage regulatory bodies to explore the potential of magic mushrooms as a feasible therapeutic option. Secure your psychedelics and mushroom delivery from Get Magic Mushrooms Canada.
Frequently Asked Questions
What can patients expect from Psilocybin-Assisted Therapy?
Patients’ experiences with Psychedelic-assisted therapy (PAT) can greatly differ. To ensure a positive outcome, it is crucial to prepare thoroughly and follow specific steps. Before taking the substance, patients must undergo an extensive screening and mental readiness assessment.
- Pre-Session Preparation: Patients are evaluated comprehensively. The therapist discusses the patient’s goals and expectations to set the intentions for the session. The therapist also outlines the potential impact of the process and what the patient should expect during the session.
- The Session: Patients receive a regulated dose of the substance within a tranquil, distraction-free environment to promote relaxation and self-reflection. The therapist provides ongoing support and guidance throughout the session.
- Post-Session Integration Therapy: This therapy helps patients interpret and process their experiences. The following sessions provide continued support and counselling to reinforce the insights and changes achieved during therapy.
What effect does psilocybin have on the brains of distressed patients?
Psilocybin interacts with the brain by binding to serotonin receptors, particularly the 5-HT2A receptor. This interaction can lead to alterations in perception, mood, and cognition, resulting in significant shifts in consciousness, emotional revelations, and new perspectives.
Is psilocybin therapy available to everyone?
Psilocybin therapy is not suitable for everyone. Patients with specific mental health conditions or existential distress are thoroughly screened to exclude those with a history of psychosis.
Related Articles:
